Skip to main content

Table 2 Change in weight and BMI from double-blind acute phase baseline

From: Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment

 

Baseline N = 122

Mean change (from double-blind acute phase baseline)

6-week double-blind mean

6-month extension mean

Current study mean

Month 12 (OC)

Month 24 (OC)

n

Mean

n

Mean

Weight, kg

75.4

75.6

76.3

113

+1.8

55

+0.8

BMI, kg/m2

26.6

26.7

27.0

113

+0.7

55

+0.3

  1. Month 12 = 6 months of extension +6 months of maintenance treatment; month 24 = 6 months of extension +18 months of continuation treatment (patients randomized to lurasidone in the initial double-blind acute treatment study had an additional 6 weeks of exposure to lurasidone)
  2. BMI body mass index, OC observed case analysis